Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor-Reference-Cited by-同舟云学术

Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor

Published:2019-01-29 Issue:3 Volume:12 Page:267-275
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Garg Varun¹,Shen Jinshan²,Li Chonghua¹,Agarwal Sagar³,Gebre Asfiha¹,Robertson Sarah¹,Huang Jiayin⁴,Han Linda¹,Jiang Licong⁵,Stephan Kristin¹,Wang Linda T.¹,Lekstrom‐Himes Julie¹

Affiliation:

1. Vertex Pharmaceuticals Incorporated Boston Massachusetts USA

2. Gossamer Bio San Diego California USA

3. Alnylam Pharmaceuticals Cambridge Massachusetts USA

4. Astellas Pharma Global Development, Inc. Northbrook Illinois USA

5. Vertex Pharmaceuticals, Inc. San Diego California USA

Funder

Vertex Pharmaceuticals

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12610

Reference9 articles.

1. Cystic Fibrosis Foundation.Cystic Fibrosis Foundation Patient Registry 2015 Annual Data Report(Cystic Fibrosis Foundation Bethesda MD 2016).

2. Cystic Fibrosis Trust.UK Cystic Fibrosis Registry 2015 Annual Data Report(Cystic Fibrosis Trust London UK 2016).

3. Symdeko [package insert].Boston MA:Vertex Pharmaceuticals Incorporated;2018.

4. Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

5. Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically‐based pharmacokinetic modeling of the drug–drug interaction between ivacaftor and lefamulin in cystic fibrosis patients;CPT: Pharmacometrics & Systems Pharmacology;2024-02

2. Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis;Respiratory Research;2023-12-16

3. Trials and tribulations of highly effective modulator therapies in cystic fibrosis;Paediatric Respiratory Reviews;2023-12

4. Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration;Journal of Cystic Fibrosis;2023-11

5. The multiple ubiquitination mechanisms in CFTR peripheral quality control;Biochemical Society Transactions;2023-05-04